WO2008083130A3 - Amorphous and crystalline form a of carvedilol phosphate - Google Patents

Amorphous and crystalline form a of carvedilol phosphate Download PDF

Info

Publication number
WO2008083130A3
WO2008083130A3 PCT/US2007/088774 US2007088774W WO2008083130A3 WO 2008083130 A3 WO2008083130 A3 WO 2008083130A3 US 2007088774 W US2007088774 W US 2007088774W WO 2008083130 A3 WO2008083130 A3 WO 2008083130A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous
crystalline form
carvedilol phosphate
phosphate
carvedilol
Prior art date
Application number
PCT/US2007/088774
Other languages
French (fr)
Other versions
WO2008083130A2 (en
Inventor
Atul Vishvanath Patil
Narayanan Badri Vishwanathan
Indu Bhushan
Gade Srinivas Reddy
Mallepalli Srinivas Reddy
Kasaraddy Padmaja Reddy
Original Assignee
Reddys Lab Ltd Dr
Reddys Lab Inc Dr
Atul Vishvanath Patil
Narayanan Badri Vishwanathan
Indu Bhushan
Gade Srinivas Reddy
Mallepalli Srinivas Reddy
Kasaraddy Padmaja Reddy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Reddys Lab Inc Dr, Atul Vishvanath Patil, Narayanan Badri Vishwanathan, Indu Bhushan, Gade Srinivas Reddy, Mallepalli Srinivas Reddy, Kasaraddy Padmaja Reddy filed Critical Reddys Lab Ltd Dr
Publication of WO2008083130A2 publication Critical patent/WO2008083130A2/en
Publication of WO2008083130A3 publication Critical patent/WO2008083130A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to amorphous carvedilol phosphate, processes of preparation, and its pharmaceutical compositions.
PCT/US2007/088774 2006-12-26 2007-12-24 Amorphous and crystalline form a of carvedilol phosphate WO2008083130A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN2424CH2006 2006-12-26
IN2424/CHE/2006 2006-12-26
US89471207P 2007-03-14 2007-03-14
US60/894,712 2007-03-14
IN1279CH2007 2007-06-20
IN1279/CHE/2007 2007-06-20

Publications (2)

Publication Number Publication Date
WO2008083130A2 WO2008083130A2 (en) 2008-07-10
WO2008083130A3 true WO2008083130A3 (en) 2008-11-13

Family

ID=39523667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088774 WO2008083130A2 (en) 2006-12-26 2007-12-24 Amorphous and crystalline form a of carvedilol phosphate

Country Status (1)

Country Link
WO (1) WO2008083130A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
LT2489659T (en) 2004-06-24 2018-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RS60205B1 (en) 2005-12-28 2020-06-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2195292B1 (en) 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
WO2009047800A2 (en) * 2007-10-09 2009-04-16 Lupin Limited Oral controlled release composition of carvedilol
WO2010089760A2 (en) * 2008-05-29 2010-08-12 Alkem Laboratories Ltd. Controlled release, multiple unit pharmaceutical compositions
LT2821400T (en) 2009-03-20 2018-02-12 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
CN109966264A (en) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 Pharmaceutical composition and its application
WO2015048492A1 (en) * 2013-09-27 2015-04-02 Basf Corporation Pressure release device for adsorbed gas systems
KR20170063954A (en) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof

Also Published As

Publication number Publication date
WO2008083130A2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2008002683A3 (en) Polymorphous forms of carvedilol phosphate
WO2006024024A3 (en) Solid and crystalline ibandronate sodium and processes for preparation thereof
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2007093627A3 (en) Biocidal composition
WO2008066935A3 (en) Crystalline forms of tigecycline and processes for preparation thereof
WO2010031720A3 (en) Novel antibody formulation
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2008070072A3 (en) Carvedilol forms, compositions, and methods of preparation thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2012085927A3 (en) Tadalafil compositions
WO2010049449A3 (en) Novel salts of sunitinib
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2010008735A3 (en) Solid states of o-desmethylvenlaf axine salts
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2007125521A3 (en) Polymorphic form of zoledronic acid and processes for their preparation
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2008081268A3 (en) Pharmaceutical compositions of entacapone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869862

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07869862

Country of ref document: EP

Kind code of ref document: A2